Understanding HIV prevention preferences among cisgender women and trans individuals
Stick2PrEP Women/Trans Individuals: Increasing Pre-Exposure Prophylaxis (PrEP) Uptake, Adherence, and Retention in Care, and Understanding PrEP Preferences Among Predominantly Black and Latinx Cisgender Women and Transgender Individuals
This study is trying to understand what cisgender women and trans individuals think about HIV prevention methods like PrEP and how their choices affect their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 175 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05165745 on ClinicalTrials.gov |
What this trial studies
This study evaluates the preferences and attitudes towards HIV prevention methods, specifically pre-exposure prophylaxis (PrEP), among cisgender women and trans individuals. Participants will complete online questionnaires regarding their demographics, health determinants, and preferences for PrEP modalities. The study will also conduct qualitative interviews with individuals who choose not to start or discontinue PrEP to explore their decision-making processes. Additionally, participants taking PrEP will provide dried blood spot samples to measure medication levels and receive personalized feedback on their adherence to the regimen.
Who should consider this trial
Good fit: Ideal candidates include cisgender women and trans individuals who are either considering starting PrEP, currently taking it, or have previously discontinued it.
Not a fit: Patients who are living with HIV or cannot provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how to effectively promote and support PrEP use among at-risk populations, potentially reducing HIV infection rates.
How similar studies have performed: Other studies have shown success in understanding patient preferences for HIV prevention methods, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cisgender women and trans individuals who have an indication for PrEP and have 1) decided to take PrEP, 2) decided not to take PrEP, or 3) decided to discontinue PrEP Exclusion Criteria: * Cannot provide informed consent * Living with HIV
Where this trial is running
New York, New York
- Columbia University Medical Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Magdalena Sobieszczyk, MD, MPH — Columbia University
- Study coordinator: Deborah Theodore, MD
- Email: dat2132@cumc.columbia.edu
- Phone: 2123052201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.